Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gangat Naseema, Elbeih Azeem, Ghosoun Nour, McCullough Kristen, Aperna Fnu, Johnson Isla M, Abdelmagid Maymona, Al-Kali Aref, Alkhateeb Hassan B, Begna Kebede H, Elliott Michelle, Mangaonkar Abhishek, Matin Aasiya, Saliba Antoine N, Hefazi Torghabeh Mehrdad, Litzow Mark R, Hogan William, Shah Mithun, Patnaik Mrinal M, Pardanani Animesh, Badar Talha, Murthy Hemant, Foran James, Palmer Jeanne, Sproat Lisa, Khera Nandita, Arana Yi Cecilia, Yates Samuel, Sneider Abigail, Dworkin Emily, Patel Anand A, Bazinet Alexandre, Senapati Jayastu, Bataller Alex, DiNardo Courtney, Kadia Tapan, Tefferi Ayalew
Аннотация
Patients with newly diagnosed acute myeloid leukemia (ND-AML) derive variable survival benefit from venetoclax + hypomethylating agent (Ven-HMA) therapy. The primary objective in the current study was to develop genetic risk models that are predictive of survival and are applicable at the time of diagnosis and after establishing treatment response. Among 400 ND-AML patients treated with Ven-HMA at the Mayo Clinic, 247 (62%) achieved complete remission with (CR) or without (CRi) count recovery. Multivariable analysis-derived hazard ratios (HR), including 1.8 for European LeukemiaNet (ELN) adverse karyotype, 4.7 for KMT2Ar, 1.7 for TP53 MUT, 2.6 for KRAS MUT, and 2.1 for IDH2 WT were applied to develop an HR-weighted risk model: low, intermediate, and high; respective median survival censored for allogeneic stem cell transplant (ASCT) (3-year survival) were "not reached" (67%), 19.1 (33%), and 7.1 months (0%). In patients achieving CR/CRi, adverse karyotype, KMT2Ar, KRAS MUT, IDH2 WT predicted inferior survival, allowing for a complementary response-stratified risk model. The model was externally validated and was shown to be superior to the ELN 2024 risk model (AIC 179 vs. 195 and AUC 0.77 vs. 0.69). Survival was inferior with failure to achieve CR/CRi or not receiving ASCT; 3-year survival for high-risk with or without ASCT was 42% versus 0% (p < 0.01); intermediate 72% versus 43% (p = 0.06); and low-risk 88% versus 78% (p = 0.53). The Mayo genetic risk models offer pre-treatment and response-based prognostic tools for ND-AML treated with Ven-HMA. The current study underscores the prognostically indispensable role of achieving CR/CRi and ASCT.